Cleveland Clinic inked a strategic collaboration with bio-analytics company Aspira Women’s Health on an initiative to improve artificial intelligence-powered diagnostics for women’s health.
The two organizations will collaborate on research projects aimed at discovering and validating biomarker signatures, as well as developing analytical models to improve diagnostic accuracy, clinical utility and patient care.
A framework for future expansion is also included in the agreement, according to the announcement, for work on data generation, translational development, clinical research initiatives and more.
Through the partnership, the organizations aim to expand patient sample access, enhance clinical validation capabilities and support accelerated development and commercialization of multiomic diagnostics for women’s health.
The collaboration will be jointly led by Kevin Elias, M.D. of Cleveland Clinic, and Todd Pappas, Ph.D. of Aspira Women’s Health, alongside multidisciplinary research teams.
Elias said in a statement that the organizations believe integrating multiomic biomarkers with advanced AI-driven analytics “represents a highly promising frontier in precision diagnostics.”
“We have already demonstrated the potential of this approach to improve ovarian cancer diagnostics, and we believe it can be applied more broadly across women’s health,” Elias said. “This collaboration brings together complementary scientific, clinical, translational and commercial expertise with the shared goal of advancing more accurate noninvasive tools that can meaningfully improve patient care and clinical decision-making.”